Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 17/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 16/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.62 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.62 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.62 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21343038 | 0.94 | ADORA2B (0.59) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL29399586 | 0.94 | ADORA2B (0.59) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL3219385 | 0.93 | ADORA2B (0.59) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL3219379 | 0.92 | ADORA2B (0.57) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL21343076 | 0.90 | ADORA2B (0.66) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL21343071 | 0.90 | ADORA2B (0.65) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL242945 | 0.89 | ADORA2B (0.62) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL21343680 | 0.89 | ADORA2B (0.68) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL838239 | 0.89 | ADORA2B (0.62) | ADORA2BADORA2AADORA1ADORA3PLK4 | |
| SCHEMBL21343082 | 0.89 | ADORA2B (0.62) | ADORA2BADORA2AADORA1ADORA3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595630-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | Gilead Sciences, Inc. (US) | 2013-05-29 | — | — | EP | claimed |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2012-08-30 | — | — | US | claimed |
| US-20120003329-A1 | Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension | GILEAD SCIENCES, INC. | 2012-01-05 | — | — | US | claimed |
| WO-2012003220-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING PULMONARY HYPERTENSION | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | claimed |
| US-20110184002-A1 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-07-28 | — | — | US | claimed |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-03-04 | — | — | US | claimed |
| US-7625881-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2009-12-01 | — | — | US | claimed |
| EP-1996201-A2 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2008-12-03 | — | — | EP | claimed |
| EP-1891070-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2007109547-A2 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-09-27 | — | — | WO | claimed |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD SCIENCES, INC. | 2007-09-20 | — | — | US | claimed |
| WO-2006138376-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060293283-A1 | Prodrugs of A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2006-12-28 | — | — | US | claimed |
| EP-3103454-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | Gilead Sciences, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2694074-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | Gilead Sciences, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD SCIENCES, INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2006138376-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138376-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293283-A1 | Prodrugs of A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20120003329-A1 | Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension | ADORA2B, ADORA2A, TBXA2R | ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885 |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20110184002-A1 | METHOD OF TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-20060293283-A1 | Prodrugs of A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.